MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MIP-3 alpha/CCL20 Protein, Human

MCE 国际站：MIP-3 alpha/CCL20 Protein, Human

MIP-3 alpha/CCL20 Protein, Human 是一种 CC 趋化因子，可吸引淋巴细胞和轻微的中性粒细胞，通过与趋化因子受体 CCR6 结合并发挥作用。可诱导细胞内钙离子动员，介导癌症、各种自身免疫性疾病以及抗菌作用。MIP-3 alpha/CCL20 Protein, Human 是一种由 E. coli 表达的重组人 CCL20 (A27-M96)。

Synonyms: rHuMIP-3α/CCL20; C-C motif chemokine 20; MIP3A; SCYA20

Species: Human

Source: E. coli

Biological Activity: Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 10.0-50.0 ng/mL.

研究背景：CCL20, also known as macrophage inflammatory protein 3 alpha (MIP-3-alpha) and liver-activated regulatory chemokine (LARC), is a small cytokine belonging to the CC chemokine family and is located on chromosome 2 in the human genome. It is expressed at lower levels in the thymus, testis, prostate and intestine. CCL20 binds to and acts as a chemokine receptor CCR6 and synergistically inhibits the function of CD8 T cells with CCR6. CCL20 has antimicrobial activity and has been implicated in autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis, as well as oncological diseases. It can induce Tregs to invade tumor tissue, recruit dendritic cells to promote immunosuppression, and induce endothelial cell proliferation and neointima formation.

蛋白编号：P78556 (A27-M96)

基因 ID：6364

产品分类：细胞因子和生长因子  |  趋化因子  |  CC 趋化因子  |  趋化因子 CCL20

Categories：Cytokines and Growth Factors  |  Chemokine & Receptors  |  CC Chemokines  |  MIP-3 alpha/CCL20

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。